Company / Cost of Revenue
RIGEL PHARMACEUTICALS INC Cost of Revenue History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$19.6M
FY2025
5-year range
$1.1M / $19.6M
FY2021-FY2025
Trend
+5.2%
vs FY2024
Sector context
#64 of 85
Health Care
What the data says
RIGEL PHARMACEUTICALS INC's cost of revenue of $20M is lower than 75% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 5 consecutive years, from $895,000 in FY2020 to $20M in FY2025.
Based on SEC 10-K filings.
$20M in FY2025 with a 5-year CAGR of +85.4%.
Increased from $7M to $20M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +123.9%
- 5-Year CAGR
- +85.4%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 85This company $19.6M Sector average $2.0B
▼
-99.0% below sector average
Key checks
Key Insights
- RIGEL PHARMACEUTICALS INC's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +85.4%, indicating consistent growth.
- In FY2025, cost of revenue increased 5.2% year-over-year.
- Ranks #64 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.6M | +5.2% |
| FY2024 | $18.6M | +162.3% |
| FY2023 | $7.1M | +306.5% |
| FY2022 | $1.7M | +61.5% |
| FY2021 | $1.1M | +21.0% |
| FY2020 | $895.0K | -1.2% |
| FY2019 | $906.0K | +215.7% |
| FY2018 | $287.0K | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026